Research Analysts Offer Predictions for Genfit S.A.’s FY2024 Earnings (NASDAQ:GNFT)

Genfit S.A. (NASDAQ:GNFT) – Stock analysts at Leerink Partnrs boosted their FY2024 EPS estimates for shares of Genfit in a note issued to investors on Thursday, September 19th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings per share of $0.65 for the year, up from their prior estimate of $0.52. The consensus estimate for Genfit’s current full-year earnings is $0.56 per share.

Separately, HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Genfit in a report on Friday, September 20th.

Genfit Stock Performance

Genfit stock opened at $5.30 on Monday. The firm’s fifty day simple moving average is $4.25 and its 200-day simple moving average is $4.08. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.94 and a current ratio of 2.94. Genfit has a 1-year low of $2.89 and a 1-year high of $6.05.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Genfit stock. Optiver Holding B.V. increased its position in Genfit S.A. (NASDAQ:GNFT) by 2,229.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 82,359 shares of the company’s stock after acquiring an additional 78,823 shares during the quarter. Optiver Holding B.V. owned about 0.17% of Genfit worth $315,000 at the end of the most recent quarter. 2.24% of the stock is currently owned by institutional investors and hedge funds.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.